FMC (FMC) faces several risks to its 2025 outlook such as increasing leverage, limited free cash flow, and ongoing headwinds for its diamide products, BofA Securities said in a Wednesday note.
The company reported its Q4 results late Tuesday, with higher adjusted earnings and revenue, and issued its outlook for Q1 and 2025. According to BofA Securities, FMC's Q1 guidance was "very soft" and 2025 targets were "weak" overall.
"FMC's diamide updates included a worse-than-expected outlook," the investment firm said, noting that the business' generic competition continued to expand.
BofA Securities said the company also faces the risk of downgrade to a non-investment grade credit rating and growth initiatives could take longer than expected to deliver benefits.
BofA Securities downgraded FMC to underperform from neutral and lowered its price target to $48 from $61.
Shares of FMC were down more than 33% in recent Wednesday trading.
Price: 35.85, Change: -18.19, Percent Change: -33.66
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。